Bradley J. Monk, MD, FACOG, FACS


Dr. Monk on the Emergence of NaPi2b as a Target in Ovarian Cancer

January 5th 2022

Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

Cervical Cancer Management: Looking Toward the Future of Care

December 8th 2021

Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.

Metastatic Cervical Cancer: Practical Considerations for Tisotumab Vedotin Use

December 8th 2021

Experts share their experience and thoughts on the use of tisotumab vedotin as the management of metastatic cervical cancer continues to evolve.

Metastatic Cervical Cancer: ADC Adverse Event Management

December 2nd 2021

Considerations for adverse event management with tisotumab vedotin use in patients with metastatic cervical cancer.

Tisotumab Vedotin: A Second-Line ADC Approval in Metastatic Cervical Cancer

December 2nd 2021

Shared insight on the approval of tisotumab vedotin, an antibody-drug conjugate, in the second-line setting of metastatic cervical cancer.

Metastatic Cervical Cancer: Moving Immune Checkpoint Inhibition to the Front Line

November 24th 2021

Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.

Second-Line Immune Checkpoint Inhibition in Metastatic Cervical Cancer

November 24th 2021

An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.

Unmet Needs in Second-Line Therapy for Metastatic Cervical Cancer

November 18th 2021

Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.

Metastatic Cervical Cancer: Interpreting Data From KEYNOTE-826

November 18th 2021

Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.

KEYNOTE-826: Immune Checkpoint Inhibition in Metastatic Cervical Cancer

November 10th 2021

Considerations for the KEYNOTE-826 trial, which tested pembrolizumab in combination with chemotherapy in patients with metastatic cervical cancer.

Chemotherapy and Antiangiogenesis Therapy in Metastatic Cervical Cancer

November 10th 2021

Looking at the current treatment landscape in metastatic cervical cancer, experts consider the role of frontline chemotherapy and antiangiogenesis therapy.

Ongoing Clinical Trials in Locally Advanced Cervical Cancer

November 3rd 2021

Closing out their discussion on locally advanced cervical cancer, panelists discuss ongoing clinical trials and the potential of the involved novel therapies.

Locally Advanced Cervical Cancer: Interpreting the OUTBACK Trial

November 3rd 2021

Considerations for the negative results of the OUTBACK trial, which tested adjuvant chemotherapy in locally advanced cervical cancer.

Locally Advanced Cervical Cancer: Surgery and Standard of Care Therapy

October 27th 2021

Focusing on locally advanced cervical cancer, experts elucidate the role of surgery and standard of care therapy.

What is the Current Role of Biomarker Testing in Cervical Cancer?

October 27th 2021

The panel reflects on the current, optimal use of biomarker testing to guide the management of cervical cancer.

Role of HPV Vaccination and Screening to Prevent Cervical Cancer

October 20th 2021

A comprehensive review of the current paradigm for HPV vaccination and screening to prevent cervical cancer.

Understanding the Biology and Staging of Cervical Cancer

October 20th 2021

Experts provide a brief overview of cervical cancer, focusing on the driving biology and FIGO staging system.

Dr. Monk on Transformative KEYNOTE-826 Data in Frontline Cervical Cancer

September 18th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses outcomes with pembrolizumab plus chemotherapy in patients with recurrent or metastatic cervical cancer, as reported in the phase 3 KEYNOTE-826 trial.

Dr. Monk on the Utility of PARP Inhibitors as Maintenance Therapy in Ovarian Cancer

July 28th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.

Dr. Monk on the Mechanism of Action of VB-111 in Ovarian Cancer

June 18th 2021

Bradley Monk, MD, FACOG, FACS, discusses the mechanism of action of VB-111 in patients with ovarian cancer.